LDXHF.US Lumos Diagnostics Holdings Limited

Healthcare Biotechnology USA Stocks
0.0500 USD
Close of Nov 11, 2026
0.0400 0.2400
Market cap
USD 49.4M
P/E
-
P/B
2.16x
ROE
-22.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is LDXHF.US undervalued?

Graham number

The Graham number of Lumos Diagnostics Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lumos Diagnostics Holdings Limited fundamental analysis

No fundamental analysis for Lumos Diagnostics Holdings Limited yet.

Lumos Diagnostics Holdings Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lumos Diagnostics Holdings Limited

Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is he…

Full company profile